#China #Shanghai #biotechnology #Antengene #ATG-022

Antengene Corporation Achieves Profitability in 2026 Interim Results

Antengene Corporation Limited, a leading biotech company based in Shanghai and Hong Kong, recently announced its interim results for the first half of 2026. This marks a significant milestone for the company, as it reports its first-ever profitability, an achievement that underscores its commitment to innovative research and development in the biotech sector.

Dr. Jay Mei, the company's founder and CEO, shared some notable highlights from the recent announcement. For the period ending June 30, 2026, Antengene recorded total revenues of approximately RMB 513 million, reflecting a staggering year-on-year increase of 864.5%. The reported profit for this period was around RMB 216 million. This remarkable growth in revenue and profitability validates Antengene's strategic focus on harnessing internal innovation coupled with global partnerships.

One of the key contributors to this achievement has been the strategic licensing agreements that Antengene has successfully negotiated. Notably, an exclusive license agreement with UCB for ATG-201 (CD19 x CD3 T-cell engager) has led to an upfront payment of USD 60 million. In addition, the company has secured another exclusive licensing deal with K2 Therapeutics for ATG-106, which is expected to yield approximately USD 20 million. The potential for milestone payments and royalties from these partnerships further bolsters Antengene's financial outlook.

Advancements in Research & Development

In terms of its R&D initiatives, Antengene has made considerable progress in its clinical programs. The company’s late-stage program, ATG-022, which is a CLDN18.2 antibody-drug conjugate, recently received a Breakthrough Therapy Designation from the CDE. This advance shows promising efficacy and safety in treating gastric cancer, particularly for patients with varying levels of CLDN18.2 expression. Clinical trials for ATG-022 are progressing robustly, with the pivotal Phase III CLINCH-3 study demonstrating significant potential for its integration into standard treatment regimens.

Additionally, Antengene is expanding its capabilities in T-cell engager innovation through the development of the TriGager™ platform, which allows the engineering of next-generation logic-gated tri-specific TCEs. This platform will enhance the company's ability to tailor specific therapies and optimize the T-cell response in various cancer types, thus opening new avenues for cancer treatment.

The advancements in artificial intelligence integration into Antengene's R&D processes are also noteworthy. By leveraging AI to link multi-omics analysis with protein datasets, Antengene is identifying novel therapeutic targets and expediting the design of effective treatments for cancers with high unmet medical needs.

Looking Ahead

As Antengene positions itself for future growth, the company plans on further strengthening its internal capabilities, advancing clinical pipelines, and enhancing global partnerships. With a solid financial footing and a clear commitment to continuous innovation, Antengene is poised to create long-term value in the biotechnology space.

The interim results of 2026 not only reflect Antengene's financial success but also highlight its dedication to addressing significant health challenges through groundbreaking therapies. The industry awaits with anticipation the implications of their upcoming clinical results and potential new treatments set to emerge from their innovative pipeline.

Overall, the success recorded in the first half of 2026 signifies a pivotal moment for Antengene, showcasing its ability to execute its vision effectively, ultimately transforming the landscape of biotech therapeutic development.